heptanoic acid N'-o-tolylhydrazide | 912963-39-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: heptanoic acid N'-o-tolylhydrazide
• 英文别名: N'-(2-methylphenyl)heptanohydrazide；N'-(2-methylphenyl)heptanehydrazide
• CAS: 912963-39-4
• 化学式: C₁₄H₂₂N₂O
• 分子量: 234.341
• InChiKey: YHCZXYOUQUJSAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  庚酸 、 邻甲基苯肼盐酸盐 在 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 0.12h， 以5.8 mg的产率得到heptanoic acid N'-o-tolylhydrazide
  参考文献：
  名称：

  Structure−Activity Relationship Studies on N′-Aryl Carbohydrazide P2X₇ Antagonists

  摘要：

  N'-Aryl acyl hydrazides were identified as P2X(7) receptor antagonists. Structure-activity relationship (SAR) studies evaluated functional activity by monitoring calcium flux inhibition in cell lines expressing recombinant human and rat P2X(7) receptors. Selected analogs were assayed in vitro for their capacity to inhibit release of cytokine IL-1 beta. Compounds with potent antagonist function were evaluated in vivo using the zymosan-induced peritonitis model. A representative compound effectively attenuated mechanical allodynia in a rat model of neuropathic pain.

  DOI：

  10.1021/jm701516f

文献信息

• Acylhydrazine P2X7 antagonists and uses thereof
  申请人：Nelson W. Derek

  公开号：US20060276505A1

  公开（公告）日：2006-12-07

  The present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein D, A, m, n, R x and R y are defined in the description. The present invention also relates to pharmaceutical compositions of compounds of formula (I), which are useful for treating a disorder selected from the group consisting of chronic inflammatory pain, neuropathic pain, inflammation, neurodegeneration, depression and promoting neuroregeneration. The present invention also relates to a method for treating pain, neuropathic pain, inflammation, chronic inflammatory pain, neurodegeneration, depression and promoting neuroregeneration in a mammal using compounds of formula (II), a pharmaceutically acceptable salt, ester, amide or prodrug thereof, wherein R 3 and R 4 are defined in the description.

  本发明揭示了一种式（I）的化合物或其药学上可接受的盐或前药，其中D，A，m，n，Rx和Ry在说明中定义。本发明还涉及式（I）化合物的药物组合物，其用于治疗选择自慢性炎性疼痛、神经病理性疼痛、炎症、神经退行性疾病、抑郁症和促进神经再生的疾病。本发明还涉及一种使用式（II）化合物、其药学上可接受的盐、酯、酰胺或前药治疗哺乳动物的疼痛、神经病理性疼痛、炎症、慢性炎性疼痛、神经退行性疾病、抑郁症和促进神经再生的方法，其中R3和R4在说明中定义。
• Structure−Activity Relationship Studies on <i>N</i>′-Aryl Carbohydrazide P2X₇ Antagonists
  作者：Derek W. Nelson、Kathy Sarris、Douglas M. Kalvin、Marian T. Namovic、George Grayson、Diana L. Donnelly-Roberts、Richard Harris、Prisca Honore、Michael F. Jarvis、Connie R. Faltynek、William A. Carroll

  DOI：10.1021/jm701516f

  日期：2008.5.1

  N'-Aryl acyl hydrazides were identified as P2X(7) receptor antagonists. Structure-activity relationship (SAR) studies evaluated functional activity by monitoring calcium flux inhibition in cell lines expressing recombinant human and rat P2X(7) receptors. Selected analogs were assayed in vitro for their capacity to inhibit release of cytokine IL-1 beta. Compounds with potent antagonist function were evaluated in vivo using the zymosan-induced peritonitis model. A representative compound effectively attenuated mechanical allodynia in a rat model of neuropathic pain.